In January 2016, letters were sent to healthcare professionals to notify about safety information for:
- Fingolimod (
▼): risks related to effects on the immune system
- Erlotinib (
): first-line maintenance indication now restricted to patients with a tumour that has an EGFR-activating mutation
Article citation: Drug Safety Update volume 9 issue 6 February 2016: 3.
Published 17 February 2016